Vericel Corporation

Stage 3 · Topping · week 6

As of Oct 22, 2026, Vericel is in Stage 3, the topping phase, now in week 6 (since Sep 16, 2026). It closed at $42.97, 11.1% below its 52-week high and above its 200-day average, which is rising.

$42.97

+4.96% today

$2.2B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is VCEL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 32w

S4 16w

S4 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 10w → S2 32w → S3 5w → S2 10w → S3 2w → S4 6w → S1 2w → S2 12w → S3 6w → S4 13w → S1 1w → S4 16w → S1 9w → S2 2w → S1 1w → S4 17w → S1 3w → S2 12w → S3 5w current

Total tracked: 166 weeks across 20 stage runs.

VCEL among Biotechnology142nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…142	VCELVericel Corporation	Stage 3 · wk 6	68	+10.8%

vs 52W High

-11.1%

$29.34 lo$48.31 hi

11.1% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 6

1w13w26w

Week 6, distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

11.5%

200 DMA: $38.54 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

1.18x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↗ ⇈

Short-term trend rising gently, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+10.8%

-4.6%

+24.9%

YTD

+20.7%

+17.9%

Scan Membership

Breakout Watch

Latest: 2024-12-03

8 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 6 · Vol 1.18x

2026-10-21S3

Wk 6 · Vol 0.73x

2026-10-20S3

Wk 5 · Vol 0.93x

2026-10-19S3

Wk 5 · Vol 0.65x

2026-10-16S3

Wk 5 · Vol 1.45x

2026-10-15S3

Wk 5 · Vol 1.19x

2026-10-14S3

Wk 5 · Vol 0.76x

2026-10-13S3

Wk 4 · Vol 1.01x

2026-10-12S3

Wk 4 · Vol 0.85x

2026-10-09S3

Wk 4 · Vol 0.98x

2026-10-08S3

Wk 4 · Vol 1.46x

2026-10-07S3

Wk 4 · Vol 1.27x

Moving averages & range

50 DMA

$40.76

200 DMA

$38.54

52W High

$48.31

52W Low

$29.34

5D Low

$40.13

Resistance levels (recent highs)

20d High

$42.97

60d High

$47.61

120d High

$48.31

250d High

$48.31

Next resistance

+10.8%

to 60d High

P/E (TTM)

90.8

Forward 50.4

ROE

+7.2%

Profit margin +7.9%

Dividend Yield

0.00%

P/B 5.9

Vericel: quick answers

What stage is Vericel in?

As of Oct 22, 2026, Vericel (VCEL) is in Stage 3, the topping phase. It entered Stage 3 on Sep 16, 2026 and is in week 6. What the four stages mean

Is Vericel in an uptrend?

Its uptrend has stalled. Vericel is in Stage 3, the topping phase that follows an advance. It trades 11.5% above its 200-day average, which is rising.

How far is Vericel from its 52-week high?

Vericel closed at $42.97 on Oct 22, 2026, 11.1% below its 52-week high of $48.31. Its 52-week low is $29.34.

How has Vericel performed over the past year?

As of Oct 22, 2026, Vericel is up 17.9% over the past year and up 20.7% so far in 2026.

Which sector and industry is Vericel in?

Vericel is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.